Equities

Dizal Jiangsu Pharmaceutical Co Ltd

688192:SHH

Dizal Jiangsu Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)46.18
  • Today's Change-1.56 / -3.27%
  • Shares traded3.20m
  • 1 Year change+4.88%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7481,4162,075
Total Receivables, Net869.299.02
Total Inventory235.07--
Prepaid expenses534228
Other current assets, total------
Total current assets9101,4732,112
Property, plant & equipment, net105106104
Goodwill, net------
Intangibles, net462492475
Long term investments------
Note receivable - long term2.232.5350
Other long term assets------
Total assets1,4962,0822,746
LIABILITIES
Accounts payable109153132
Accrued expenses585034
Notes payable/short-term debt2021.501.65
Current portion long-term debt/capital leases232117
Other current liabilities, total572227
Total current liabilities448248212
Total long term debt1876471
Total debt4128789
Deferred income tax------
Minority interest------
Other liabilities, total1211--
Total liabilities648323283
SHAREHOLDERS EQUITY
Common stock408407404
Additional paid-in capital2,9542,7572,729
Retained earnings (accumulated deficit)(2514)(1406)(670)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity8491,7582,463
Total liabilities & shareholders' equity1,4962,0822,746
Total common shares outstanding408407404
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.